Glenmark: Environment challenging, see 20% growth in FY14

North America is the largest pharmaceutical market for the drug firms of the world. And the importance of this market has been highlighted by the quarterly numbers posted by Indian pharmaceutical giants. For Lupin , revenues from the US market grew ...

Glenmark Pharma sees its overall sales growing at a slower 20% this fiscal from the 38% pace logged in the last fiscal on account slowdown in India and delay in US drug approvals. Glenmark Pharma sees its overall sales growing at a slower 20% this ...

Glenmark Pharmaceuticals rose 1.35% to Rs 527.70 at 9:22 IST on BSE after consolidated net profit rose 10.9% to Rs 166.79 crore on 25.3% growth in revenue to Rs 1335.48 crore in Q4 March 2013 over Q4 March 2012. The company announced the result ...

Drug-maker Glenmark said that its specialty drugs and generics businesses performed well in the year ended March 2013. "The US, India and Russia businesses continued to maintain its high growth trajectory," said Glenn Saldanha, Chairman and Managing ...

The Specialty formulation business excluding out-licensing revenue was at Rs. 7412.94 Mn (USD 136.48 Mn) as against Rs. 5943.75Mn (USD 116.98 Mn) for the corresponding previous quarter, recording a growth of 24.72 % in Rs. term over the previous ...